In CBF‐rearranged AML (n = 48), CSF3R mutations were associated with a nonsignificant trend toward worse survival (3‐year OS: 54.0% vs. 66.9%, p = 0.700; 3‐year PFS: 44.2% vs. 59.4%, p = 0.700; respectively) (Table S2). This evidence concerns the gene CSF3R and acute myeloid leukemia.